Sponsored by News
UK-based surgical robotics firm secures more than $200M to accelerate global growth
CMR Surgical – the global surgical robotics company – has announced the successful closing of a financing round of over $200 million through a combination of equity and debt capital to support the company’s ambitious growth plans. The fundraising, which was supported by all the
Company’s existing major investors, includes a new debt investment from Trinity Capital, reflecting strong investor confidence in CMR’s vision. CMR will use the funds to accelerate commercial expansion of the Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching Versius in the United States – and to continue advancing surgical robotics innovation and product development, including the launch of the newly enhanced Versius Plus. Versius, the second most utilised soft tissue
surgical robot in the world, has been used to complete more than 30,000 surgical cases globally in more than 30 different countries across a wide range of specialties including colorectal, general, gynaecology, thoracic and urology surgeries. CMR is also actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, which is the world’s first multicentre prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial, further demonstrating the versatility and capability of Versius in new surgical applications.
Massimiliano Colella, Chief Executive Officer at
CMR Surgical, commented: “CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the US, while continuing to penetrate deeper into existing markets.” Rob Lake, Senior Managing Director, Life
Sciences at Trinity Capital, added: “Trinity Capital is excited to partner with CMR Surgical at this important juncture. CMR has established itself
as a trailblazer in surgical robotics, with Versius already proving its value to surgeons and patients worldwide. We are confident in CMR’s vision and leadership, and our investment reflects our belief that Versius will continue to drive a new era in minimally invasive surgery. We look forward to supporting CMR as it continues to scale and transform surgical care on a global level.” Dan Moore, Non-Executive Chairman at CMR
Surgical, added: “The recent funding is a strong vote of confidence in the future of surgical robotics and in CMR as a leader within this space. This investment is a significant endorsement of Max and his leadership team and provides them with the resources needed to execute on their strategic plan. We are pleased to have the continued support of our investors as we embark on this next phase of growth.” UK Science Minister and Oxford Cambridge Corridor Champion, Lord Vallance said: “This successful funding round of more than $200M is a clear vote of confidence in the company, the potential of surgical robotics, and in the UK’s life science ecosystem, which continues to produce innovative companies at an impressive rate. “We will continue to back world-class innovation and companies like CMR Surgical as they realise their global ambitions and support the creation of high-quality jobs in the UK.”
Hospital cuts SSIs in patients undergoing spine surgery by 78%
A reduction of 78.8% in surgical site infections in patients undergoing spine surgery was presented at the 25th Annual Scientific Conference of the Canadian Spine Society by researchers from the University of Sherbrooke. The study showed that patients who received presurgical Steriwave nasal photodisinfection had 78.8% fewer surgical site infections (SSIs) compared to the control group (p=0.021).
Other highlights from the study data include:
l Decreased hospital stay: The aPDT group experienced a shorter average hospital stay of 4.9 days versus 7 days in the non-aPDT group (30% reduction, p=0.017), enhancing patient recovery and optimising healthcare resources.
l Pharmacoeconomics: Based on an estimated cost of $50,000 per SSI, return on the Steriwave investment was greater than $17 per $1 dollar spent on the technology deployment.
Dr. Bernard LaRue, MD, a Spinal Surgeon and Director of Orthopaedic Surgery at Université de Sherbrooke,
commented: “Success in infection prevention is a team effort, and compliance is critical. Given its positive impact, we are keen to find ways to extend Steriwave’s benefits to patients undergoing urgent surgeries, where consistent application can be more challenging. We will also be expanding its use to joint replacement surgery patients as part of our ongoing commitment to improving infection rates and patient outcomes.”
Dr. Simon Sinclair, Ondine Biomedical’s Chief Medical Officer, commented, “These results from the University of Sherbrooke underscore the safety and efficacy of Steriwave in reducing SSIs following major surgery. Surgical site infections are potentially devastating for patients and their families, and the clinicians we’re working with are happy to have a fast, effective, and easy-to-implement solution. Steriwave is now being used to enhance patient safety and reduce infection in many of Canada’s top hospitals, as well as in multiple NHS Trusts in the UK.” Ondine has partnered with Mölnlycke Health Care, a global MedTech leader specialising in wound care and surgical solutions, to distribute Steriwave in the UK, EU, and Middle East markets.
Reference 1. Moskven E et al. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6), E550–E560.
May 2025 I
www.clinicalservicesjournal.com 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
